XTL Biopharmaceuticals Ratios and Metrics

Market cap in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Apr '26 Apr 28, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Market Capitalization	17	82	19	22	47	50	Upgrade
Market Cap Growth	-71.11%	327.50%	-14.63%	-52.02%	-7.60%	108.51%	Upgrade
Enterprise Value	16	75	11	7	37	38	Upgrade
Last Close Price	0.02	0.07	0.04	0.04	0.09	0.10	Upgrade
PE Ratio	-	-	-	-	34.41	-	Upgrade
PS Ratio	5.22	49.63	-	-	-	-	Upgrade
PB Ratio	-107.56	4.12	2.38	1.59	2.81	4.34	Upgrade
P/TBV Ratio	-	-	2.88	1.76	3.02	4.85	Upgrade
EV/Sales Ratio	5.04	45.74	-	-	-	-	Upgrade
Debt / Equity Ratio	-1.83	0.03	-	-	-	-	Upgrade
Net Debt / Equity Ratio	3.68	-0.18	-0.90	-0.93	-1.15	-1.67	Upgrade
Net Debt / EBITDA Ratio	-	0.51	2.63	4.23	5.95	6.38	Upgrade
Net Debt / FCF Ratio	-	0.60	2.84	4.13	5.84	7.10	Upgrade
Asset Turnover	0.62	0.08	-	-	-	-	Upgrade
Quick Ratio	0.46	0.56	9.74	19.90	26.52	23.79	Upgrade
Current Ratio	0.70	0.61	9.93	20.35	27.00	24.10	Upgrade
Return on Equity (ROE)	-577.13%	-26.83%	-57.31%	-28.89%	9.73%	-58.34%	Upgrade
Return on Assets (ROA)	-240.56%	-24.74%	-14.46%	-10.18%	-9.82%	-8.64%	Upgrade
Return on Capital Employed (ROCE)	12742.60%	-34.20%	-34.50%	-22.00%	-16.10%	-15.20%	Upgrade
Earnings Yield	-124.78%	-4.59%	-33.65%	-21.22%	2.91%	-18.84%	Upgrade
FCF Yield	-	-7.47%	-13.35%	-14.18%	-7.01%	-5.43%	Upgrade
Buyback Yield / Dilution	-54.39%	-29.23%	0.00%	11.48%	-19.71%	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.